Rain Therapeutics Continues to Strengthen its Leadership Team with Key Appointments
February 08, 2022 08:00 ET
|
Rain Therapeutics
– Industry veterans from Loxo/Lilly, Gilead, Seagen and AltruBio join Rain to expand clinical and regulatory operations – – In addition, Rain announces Advisory role to the CEO and Leadership team...
Rain Therapeutics to Present at SVB Leerink Global Healthcare Conference
January 31, 2022 08:00 ET
|
Rain Therapeutics
NEWARK, Calif., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics, today announced that Avanish...
Rain Therapeutics to Present at Upcoming Virtual Investor Conferences
January 25, 2022 08:00 ET
|
Rain Therapeutics
B. Riley Securities virtual presentation scheduled for January 27th at 3:30 pm ET Guggenheim Oncology virtual fireside chat scheduled for February 10th at 4:00 pm ET NEWARK, Calif., Jan. ...
Rain Therapeutics and Roche to Collaborate on Clinical Trial of Milademetan Combination with Anti-PD-L1 Immunotherapy for Various Solid Tumor Indications
January 05, 2022 08:00 ET
|
Rain Therapeutics
NEWARK, Calif., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics, today announced a clinical...
Rain Therapeutics to Present at Upcoming Investor Conferences
December 21, 2021 08:00 ET
|
Rain Therapeutics
NEWARK, Calif., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics, today announced that Avanish...
Rain Therapeutics, Inc. Added to the NASDAQ Biotechnology Index
December 14, 2021 08:00 ET
|
Rain Therapeutics
NEWARK, Calif., Dec. 14, 2021 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics, today announced it will be added...
Rain Therapeutics to Present at Upcoming Investor Conferences
November 22, 2021 10:05 ET
|
Rain Therapeutics
NEWARK, Calif., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics, today announced that Avanish...
Rain Therapeutics Strengthens the Board of Directors and Scientific Advisory Board with Key Appointments of Leading Industry and Research Experts
April 13, 2021 08:00 ET
|
Rain Therapeutics
NEWARK, Calif., April 13, 2021 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc., a clinical-stage company developing precision oncology therapeutics, today announced the appointments of Stefani Wolff to...
Rain Therapeutics Appoints Richard Bryce, MBChB, as Executive Vice President and Chief Medical Officer
April 07, 2021 08:00 ET
|
Rain Therapeutics
NEWARK, Calif., April 07, 2021 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc., a clinical-stage company developing precision oncology therapeutics, today announced the appointment of Richard Bryce,...
Rain Therapeutics Announces a Phase 1 Trial Update for the MDM2 Inhibitor, RAIN-32, at the 32nd EORTC-NCI-AACR Virtual Symposium
October 26, 2020 08:00 ET
|
Rain Therapeutics
Late-breaking presentation highlights progression-free survival of 8 months and favorable safety in patients with well-differentiated/de-differentiated liposarcoma Findings support further evaluation...